PPCM
VYNE icon

Pillar Pacific Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Pillar Pacific Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-188
Closed -$23K – 309
2020
Q2 		$23K Buy
+188
New +$25.5K ﹤0.01% 294

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Pillar Pacific Capital Management's VYNE Position: Q3 2020 in Review

Pillar Pacific Capital Management sold out of VYNE Therapeutics (VYNE) in Q3 2020, closing a stake of 188 shares — an estimated $23K sold.

Pillar Pacific Capital Management first reported a position in VYNE in Q2 2020 and held it in 1 quarter. The position peaked at $23K in Q2 2020. 105 funds tracked by Wall St. Rank hold VYNE as of Q3 2020.

  • Pillar Pacific Capital Management reported no remaining VYNE Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pillar Pacific Capital Management sold 188 VYNE Therapeutics shares in Q3 2020, an estimated $23K.
  • Pillar Pacific Capital Management first reported a position in VYNE Therapeutics in Q2 2020 and held it in 1 quarter.
  • Pillar Pacific Capital Management's VYNE Therapeutics position peaked at $23K in Q2 2020.
  • 105 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2020.

Based on Pillar Pacific Capital Management's 13F filing for Q3 2020, filed 3 Nov 2020.